Celyad Oncology SA (NASDAQ:CYAD) was the recipient of a large drop in short interest in the month of December. As of December 31st, there was short interest totalling 18,600 shares, a drop of 63.7% from the December 15th total of 51,300 shares. Based on an average daily trading volume, of 948,700 shares, the short-interest ratio is currently 0.0 days. Currently, 0.1% of the company’s stock are sold short.
Several brokerages have recently weighed in on CYAD. Zacks Investment Research raised shares of Celyad Oncology from a “hold” rating to a “buy” rating and set a $4.25 price target for the company in a research note on Tuesday, December 28th. HC Wainwright decreased their price target on shares of Celyad Oncology from $15.00 to $13.00 and set a “buy” rating for the company in a research note on Friday, December 10th. UBS Group cut shares of Celyad Oncology from a “neutral” rating to a “sell” rating in a research note on Wednesday, December 22nd. Finally, Wells Fargo & Company cut their price target on Celyad Oncology from $20.00 to $11.00 and set an “overweight” rating for the company in a report on Tuesday. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $9.42.
An institutional investor recently bought a new position in Celyad Oncology stock. OLD Mission Capital LLC bought a new stake in Celyad Oncology SA (NASDAQ:CYAD) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 11,323 shares of the company’s stock, valued at approximately $60,000. OLD Mission Capital LLC owned about 0.07% of Celyad Oncology at the end of the most recent reporting period. 1.83% of the stock is currently owned by institutional investors.
About Celyad Oncology
Celyad Oncology SA is a clinical-stage biotechnology company, which focuses on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. It operates through the following segments: Cardiology and Immuno-Oncology. The Cardiology segment includes the company’s Cardiopoiesis, Corquest, and C-Cathez platforms.
Read More: How is an ETF different from a mutual fund?
Receive News & Ratings for Celyad Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celyad Oncology and related companies with MarketBeat.com's FREE daily email newsletter.